Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis

Jacques Donnez, Donnez J, P. Dewart, Paul J Dewart, Dewart PJ, Hedon B, Bernard Hedon, B. Hédon, A Perino, Antonio Perino, Schindler AE, Adolf E. Schindler, Blumberg J, Joëlle Blumberg, Denis Querleu, Querleu D
Fertility and Sterility · 2004 · vol. 81(2) , pp. 297–304 · doi:10.1016/j.fertnstert.2003.07.013 · PMID:14967363 · W2068104402
article OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study assessed whether the 3-month and 28-day triptorelin formulations were equivalent in achieving and maintaining medical castration in women diagnosed with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveThe present study aims at demonstrating the equivalence of the 28-day and 3-month formulations of triptorelin SR (sustained release) in terms of percentage of patients achieving castration levels of estradiol (<==50 pg/mL) 84 days after treatment initiation.DesignA phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.SettingAcademic hospitals.Patient(s)Seventy-two women with endometriosis. were treated with a single intramuscular injection of 3-month triptorelin SR, and 74 patients were treated with one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.Intervention(s)As part of two parallel treatment groups, 72 women were given a single intramuscular injection of 3-month triptorelin SR, and 74 women were given one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.Main outcome measure(s)Percentage of patients achieving castration levels of estradiol at the end of the treatment period.Result(s)Patients participated in the study until resumption of menses. Ninety-seven percent of patients given the 3-month formulation and 94% of those given the 28-day formulation were in a state of medical castration on day 84. The mean time to achieve castration was shorter for the 3-month formulation, and the duration of castration was significantly longer. The FSH and LH parameters were comparable, though not always identical.Conclusion(s)The pharmacodynamic effects of the Decapeptyl SR 3-month formulation are equivalent to those of the 28-day formulation. The 3-month formulation provides the added advantage of a longer maintenance of medical castration in women who have endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Triptorelin Pamoate Adult Chemistry, Pharmaceutical Drug Administration Schedule Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Injections, Intramuscular Luteinizing Hormone Luteinizing Hormone Luteolytic Agents Luteolytic Agents Luteolytic Agents Recurrence Time Factors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (8)

Source provenance

europepmc
last seen: 2026-07-30T06:25:42.655704+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:38.158000+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK